Ribomic (4591) rebounds

Announcement that a substance patent related to anti-interleukin-21 aptamer, for which a U.S. patent application had been filed, has received a patent grant. Also announced on the same day is the domestic Phase 3 clinical trial application for the treatment drug for achondroplasia (umedaptanib pegol).